Bcl2 Family Proteins in Carcinogenesis and the Treatment of Cancer

Overview

Journal Apoptosis

Publisher Springer

Date 2009 Jan 22

PMID 19156528

Citations 122

Authors

Anna Frenzel

Francesca Grespi

Waldemar Chmelewskij

Andreas Villunger

Affiliations

Soon will be listed here.

Abstract

Deregulation of Bcl2 family members is a frequent feature of human malignant diseases and causal for therapy resistance. A number of studies have recently shed light onto the role of pro- and anti-apoptotic Bcl2 family members in tumour-pathogenesis and in mediating the effects of classical as well as novel front-line anticancer agents, allowing the development of more efficient and more precisely targeted treatment regimens. Most excitingly, recent progress in our understanding of how Bcl2-like proteins maintain or perturb mitochondrial integrity has finally enabled the development of rational-design based anticancer therapies that directly target Bcl2 regulated events at the level of mitochondria. This review aims to give an overview on the most recent findings on the role of the Bcl2 family in tumour development in model systems of cancer, to relate these findings with observations made in human pathologies and drug-action.

Citing Articles

In Silico Born Designed Anti-EGFR Aptamer Gol1 Has Anti-Proliferative Potential for Patient Glioblastoma Cells.

Golovin A, Dzarieva F, Rubetskaya K, Shamadykova D, Usachev D, Pavlova G Int J Mol Sci. 2025; 26(3).

PMID: 39940838 PMC: 11817825. DOI: 10.3390/ijms26031072.

Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review.

Saxena R, Welsh C, He Y Front Cell Dev Biol. 2024; 12:1462339.

PMID: 39620145 PMC: 11604647. DOI: 10.3389/fcell.2024.1462339.

CD spectra reveal the state of G-quadruplexes and i-motifs in repeated and other DNA sequences.

Diggins L, Ross D, Bhanot S, Corallo R, Daley R, Patel K Biophys Rep (N Y). 2024; 5(1):100187.

PMID: 39608571 PMC: 11699388. DOI: 10.1016/j.bpr.2024.100187.

BCL-X-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

Judd A, Bawa B, Buck W, Tao Z, Li Y, Mitten M Sci Adv. 2024; 10(40):eado7120.

PMID: 39365864 PMC: 11451551. DOI: 10.1126/sciadv.ado7120.

Biological roles of THRAP3, STMN1 and GNA13 in human blood cancer cells.

Alsagaby S 3 Biotech. 2024; 14(10):248.

PMID: 39345963 PMC: 11424602. DOI: 10.1007/s13205-024-04093-5.

References

Pelengaris S, Khan M, Evan G . Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002; 109(3):321-34. DOI: 10.1016/s0092-8674(02)00738-9. View

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo P, Kitada S . Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10(5):375-88. DOI: 10.1016/j.ccr.2006.10.006. View

Willis S, Adams J . Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 2005; 17(6):617-25. PMC: 2930980. DOI: 10.1016/j.ceb.2005.10.001. View

Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K . Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res. 2003; 9(17):6410-8. View

Dai D, Wang Y, Liu M, Martinka M, Li G . Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol. 2007; 128(2):403-7. DOI: 10.1038/sj.jid.5700989. View

Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y . Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000; 60(21):5988-94. View

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

Subramanian T, Chinnadurai G . bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res. 1996; 56(17):3879-82. View

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

10.

Garrison S, Jeffers J, Yang C, Nilsson J, Hall M, Rehg J . Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008; 28(17):5391-402. PMC: 2519737. DOI: 10.1128/MCB.00907-07. View

11.

Sinicrope F, Rego R, Okumura K, Foster N, OConnell M, Sargent D . Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 2008; 14(18):5810-8. PMC: 2948480. DOI: 10.1158/1078-0432.CCR-07-5202. View

12.

Romano S, Mallardo M, Chiurazzi F, Bisogni R, DAngelillo A, Liuzzi R . The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells. Haematologica. 2008; 93(7):1039-48. DOI: 10.3324/haematol.12402. View

13.

Hemann M, Zilfou J, Zhao Z, Burgess D, Hannon G, Lowe S . Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A. 2004; 101(25):9333-8. PMC: 438977. DOI: 10.1073/pnas.0403286101. View

14.

Ionov Y, Yamamoto H, Krajewski S, Reed J, Perucho M . Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A. 2000; 97(20):10872-7. PMC: 27116. DOI: 10.1073/pnas.190210897. View

15.

Kuroda J, Puthalakath H, Cragg M, Kelly P, Bouillet P, Huang D . Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006; 103(40):14907-12. PMC: 1595449. DOI: 10.1073/pnas.0606176103. View

16.

Lee J, Soung Y, Kim S, Nam S, Kim C, Cho Y . Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis. 2004; 25(8):1371-6. DOI: 10.1093/carcin/bgh145. View

17.

Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

18.

Dias N, Stein C . Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002; 1(5):347-55. View

19.

van Delft M, Wei A, Mason K, Vandenberg C, Chen L, Czabotar P . The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006; 10(5):389-99. PMC: 2953559. DOI: 10.1016/j.ccr.2006.08.027. View

20.

Cannings E, Kirkegaard T, Tovey S, Dunne B, Cooke T, Bartlett J . Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat. 2006; 102(2):173-9. DOI: 10.1007/s10549-006-9323-8. View